• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Institute for Molecular Manufacturing

Institute for Molecular Manufacturing

Atomically Precise Manufacturing

  • IMM
  • Publications
    • IMM Reports
  • Activities
  • Public Policy
  • About
  • Support Atomically Precise Manufacturing

Search Results for: Rep027.php

IMM Report Number 28: Nanomedicine

In conjunction with Foresight Update 46

How Nanorobots Can Avoid Phagocytosis by White Cells, Part II

By Robert A. Freitas Jr.
Research Scientist, Zyvex Corp.

Robert A. Freitas  Jr.
Robert A. Freitas Jr.

Part I appeared in Foresight Update 45.

Ingestion or phagocytosis of medical nanorobots [1] by white cells will occur in a series of well-defined steps. Normally inactive white cells are activated when they encounter a foreign particle, producing a change in metabolic activity and cell shape. During contact and recognition of the foreign particle, the phagocyte plasma membrane develops a local invagination or dimple. The particle is drawn inside and the dimple closes, often pinching off to form a small vacuole or phagosome consisting of everted cell wall membrane, trapping the particle inside the cell. The phagosome then forms a phagolysosome by merging with a lysosome, whose contents (including degradative lysozymes) are released into the smaller vacuole, attacking the enclosed foreign or denatured proteins. Afterwards the phagolysosomal vacuole may be absorbed or released to the outside at the cell’s outer surface via exocytosis, producing a large membrane flow. In cultured macrophages an amount of membrane equal to the entire surface area of the cell is replaced in ~1800 sec, and macrophages may ingest up to ~25% of their volume per hour [1].

In Part I of this paper [2], we described the initial antiphagocytic strategy for medical nanorobots which is to avoid phagocyte contact, recognition, binding and activation. In Part II, we assume that this initial strategy has either failed or has not been used, in which case the medical nanorobot has been recognized by, and become transiently bound to, a phagocyte. The best nanorobot strategies at this point are first, to inhibit phagocytic engulfment, and second, to inhibit enclosure and scission of the phagosome if engulfment has begun. Let’s look at these two approaches in more detail.

Even if a medical nanorobot has been recognized and has attached to the phagocyte outer surface (typically across a ~20 nm gap bridged by ~12 nm strands), the device can still prevent complete engulfment from taking place. Macrophages challenged with a particular type of target usually bind many more targets than they ingest [3]. Fortunately, internalization is a relatively slow process and most particles that become bound to the phagocyte surface are not ingested [3]. On rare occasions, phagocytosed particles are actually expelled.

Phagocytosis is an uptake of large particles governed by the actin-based cytoskeleton. Complement-opsonized (CO) and antibody-opsonized (AO) particles are phagocytosed differently by macrophages [4] — CO particles sink into the cell, whereas AO particles are engulfed by lamellipodia which project from the cell surface. During the ingestion of CO particles, punctate structures rich in F-actin, vinculin, alpha-actinin, paxillin, and phosphotyrosine-containing proteins are distributed over the phagosome surface [4]. These foci can be detected underneath bound CO particles within 30 seconds of cell activation, and their formation requires active protein kinase C. Complement receptor-mediated internalization requires intact microtubules and is accompanied by the accumulation of vesicles beneath the forming phagosome [4]. By contrast, during the ingestion of AO particles (Fcgamma receptor mediated phagocytosis), all proteins are uniformly distributed on or near the phagosome surface. Ingestion of AO beads is blocked by tyrosine kinase inhibitors (e.g., released from or tethered to medical nanorobots), although the phagocytosis of CO particles is not [4].

Phagocytic particle ingestion can require actin assembly and pseudopod extension, two cellular events that may coincide spatially and temporally but apparently use distinct signal transduction events or pathways [5]. Medical nanorobots that have become bound to the extracellular phagocyte surface may attempt to inhibit either or both of these signal transduction pathways.

In the first case, during actin assembly, engagement of particle-bound immunoglobulin IgG ligands by receptors for the Fc portion of IgG results in receptor aggregation and recruitment of cytosolic tyrosine kinase, especially Syk [6]. The onset of uptake is accompanied by tyrosine phosphorylation of several proteins, which persists for up to 3 minutes, is concentrated at phagocytic cups and nascent phagosomes, and is correlated with the accumulation of actin filaments. Phosphorylation of tyrosine residues occurs within immunoreceptor tyrosine activation motif (ITAM) consensus sequences found in FcgammaR subunits, which allows further recruitment and activation of Syk [6]. Syk tyrosine kinase activity is required for FcgammaR-mediated actin assembly, which is controlled by several GTPases, including Rac1 and CDC42 [6]. Rac1 and CDC42 (two Rho proteins involved in the signal transduction through the Fc receptors) are required to coordinate actin filament organization and membrane extension to form phagocytic cups, to allow particle internalization during FcR-mediated phagocytosis, and are involved in the phosphotyrosine dephosphorylation required for particle internalization [7].

Actin assembly can be inhibited by Clostridium difficile toxin B, which is a general inhibitor of Rho GTP-binding proteins [7]. Inhibition of Rac1 or CDC42 severely inhibits particle internalization but not F-actin accumulation [7]. In laboratory tests with cells, inhibition (via knockout of gene expression in a mutant line) of CDC42 function results in pedestal-like structures with foreign particles at their tips on the phagocyte surface, whereas inhibition of Rac1 results in particles bound at the surface that are enclosed within thin unfused membrane protrusions, demonstrating that Rac1 and CDC42 have distinct functions and may act cooperatively in the assembly of the phagocytic cup [7]. Phagocytic cup closure and particle internalization has also been blocked when phosphotyrosine dephosphorylation is inhibited by treatment of the phagocytic cells with phenylarsine oxide, an inhibitor of protein phosphotyrosine phosphatases [7]. Ceramide also inhibits tyrosine phosphorylation in human neutrophils [8].

In the second case, during pseudopod extension, phosphatidylinositol 3-kinase (PI3K) is recruited to the plasma membrane, triggering exocytosis from an internal membrane source, as is required for pseudopod extension [6]. (Macrophage spreading on opsonized surface is accompanied by insertion into the plasma membrane of new membrane from intracellular sources [5].) One or more isoforms of PI3K are required for maximal pseudopod extension, though not for phagocytosis per se; PI3K is required for coordinating exocytic membrane insertion and pseudopod extension [5].

Pseudopod extension may be partially inhibited using wortmannin (WM) or LY294002, which are two inhibitors of PI3K [5]. Both of these specifically inhibit phagocytosis without inhibiting Fcgamma receptor-directed actin polymerization, by preventing maximal pseudopod extension. Decreasing the size of test beads, and hence the size of pseudopod extension required for particle engulfment, de-inhibited phagocytosis (in presence of these inhibitors) by up to 80% at the very smallest submicron particle sizes. For larger (nanorobot-sized) foreign particles, phagocytosis is blocked before phagosomal closure. Both compounds also inhibit macrophage spreading on opsonized surfaces (i.e., on substrate-bound IgG) [5].

Amphiphysin II associates with early phagosomes in macrophages and participates in receptor-mediated endocytosis by recruiting the GTPase dynamin to the nascent endosome. There is a signaling cascade in which PI3K is required to recruit amphiphysin II to the phagosome, after which the amphiphysin II in turn recruits dynamin to the phagosome [9]. A modified amphiphysin II molecule with its dynamin-binding site ablated away inhibits phagocytosis at the stage of membrane extension around the bound foreign particles [9]. Both phenylbutazone and chloramphenicol also have shown an inhibitory effect on the engulfment stage of phagocytosis of yeast particles by cultured human monocytes [10].

As might be expected, bacteria already employ a wide variety of strategies to avoid engulfment when physically contacted by host phagocytes [11]. Some of these strategies could in principle be mimicked by medical nanorobots. Most commonly, many important pathogenic bacteria bear substances on their surfaces that inhibit phagocytic adsorption or engulfment. Resistance to phagocytic ingestion is usually due to an antiphagocytic component of the bacterial cell surface, such as:

  1. Cell Wall Substances [11] — polysaccharide surface slime (alginate slime and biofilm polymers) produced by Pseudomonas aeruginosa; O antigen associated with LPS of E. coli (smooth strains); and K antigen (acidic polysaccharides) of E. coli or the analogous Vi (K) antigen (microcapsule) of Salmonella typhi.
  2. Fimbriae and M Protein — fimbriae in E. coli [12], and M protein and fimbriae of Group A streptococci [12]. For example, Streptococcus pyogenes has M protein, a fibrillar surface protein whose distal end bears a negative charge that interferes with phagocytosis. Enterococci also have antiphagocytic surface proteins [13], such as M protein.
  3. Capsules — polysaccharide capsules of S. pneumoniae (unless antibody is present), Treponema pallidum, Klebsiella pneumoniae, Bacteroides fragilis, and Clostridium perfringens, and the Enterococci inhibit engulfment [11-13]. Haemophilus influenzae expresses a mucoid polysaccharide capsule of thickness ~1 microbial diameter which prevents digestion by host phagocytes, although many of these bacteria remain susceptible to opsonization [12]. The protein capsule on cell surface of Yersinia pestis resists engulfment [11].

Macrophages can also bind and engulf a variety of particles in the absence of specific opsonins, a process known as nonspecific phagocytosis [14], nonopsonic phagocytosis [15], or opsonin-independent phagocytosis. Polystyrene microspheres are often used to demonstrate this. For instance, during patocytosis of hydrophobic >0.5-micron particles by phagocytes, actin-independent capping of hydrophobic polystyrene microspheres on the plasma membrane precedes actin-dependent uptake of the microspheres into the surface-connected compartments [16]. Microsphere transport from plasma membrane invaginations into spaces created by unfolding stacks of internal microvilli are inhibited by administering primaquine [16]. Studies of non-specific endocytosis and binding of liposomes by mouse peritoneal macrophages also found that particle internalization declined markedly after anchorage of the cells to polystyrene substrate [17]. Inhibitors are potentially available to medical nanorobots to halt these processes too. For example, staurosporine selectively inhibits nonspecific phagocytosis while having no effect on receptor-mediated phagocytosis [14].

What if a medical nanorobot has become partially or wholly engulfed by a phagocyte? Can the vacuole still be prevented from pinching off and separating into a free intracellular phagosome containing the nanorobot (i.e., enclosure and scission)? More research is needed, but the answer appears to be yes.

Cells normally internalize soluble ligands and small particles via endocytosis and large particles via actin-based phagocytosis. The dynamin family of GTPases mediates the membrane destabilization, constriction, fission (scission) and trafficking of endocytic vesicles from the plasma membrane, but dynamin-2 also has a role in phagocytosis by macrophages [18]. Experiments reveal that early phagosomes (vacuoles) are enriched in dynamin-2, and inactive mutant versions of this molecule, if expressed, inhibit particle internalization at the stage of membrane extension around the particle [18]. This arrest of phagocytosis resembles that seen with PI3K inhibitors, preventing the recruitment of dynamin to the site of particle binding. Dynamin is a microtubule-binding enzyme with a microtubule-activated GTPase activity; phosphorylation engages its activity. Dynamin can interact with the actin cytoskeleton to regulate actin reorganization and subsequently cell shape [19].

Observations suggest that dynamin mediates scission from the plasma membrane of both clathrin-coated pits and caveolae during distinct endocytic processes [20]. For example, dynamin-1 is a 100 kD GTPase involved in scission of endocytic vesicles from the plasma membrane. It is present in solution as tetramer, undergoes self-assembly (following its recruitment to coated pits) to form higher-order oligomers that resemble collars around the necks of nascent coated buds. GTPase hydrolysis by dynamin in these collars is thought to accompany the pinching off of endocytic vesicles — dynamin may use GTPase hydrolysis physically to drive vesiculation, or may act as a classical G protein switch, or both [21]. (Purified dynamin readily self-assembles into rings or spirals, suggesting that it probably wraps around the necks of budding vesicles and squeezes, pinching them off [22]; the large GTPase dynamin is a mechanoenzyme [23].) Different dynamin isoforms may be localized to distinct cellular compartments but provide similar scission functions during the biogenesis of nascent cytoplasmic vesicles [20]. Once again, inhibitory tools that might be employed by medical nanorobots are potentially available. For example, anti-dynamin antibodies have been used to specifically inhibit dynamin function in cultured mammalian epithelial cells, inhibiting cellular uptake of external particles in these cells [20], and to inhibit clathrin-mediated endocytosis in hepatocytes [24]. Ca++ inhibits both dynamin I GTPase [25] and dynamin II GTPase [26] and may also serve as vesiculation inhibitors for fully engulfed medical nanorobots. Alternatively, butanedione monoxime, a class II myosin inhibitor, has been shown to prevent the purse-string-like contraction that closes phagosomes while not inhibiting the initial pseudopod extension [27].

One important remaining practical question is how the various inhibitory methods that we have identified will be specifically expressed in each class of medical nanorobots, but this is an issue for another time.

Acknowledgements

The author thanks Stephen S. Flitman, M.D., and C. Christopher Hook, M.D., for helpful comments on an earlier version of this paper.

Copyright 2001 Robert A. Freitas Jr. All Rights Reserved

References

1. Robert A. Freitas Jr., Nanomedicine, Volume I: Basic Capabilities, Landes Bioscience, Georgetown, TX, 1999. See at: http://www.nanomedicine.com.

2. Robert A. Freitas Jr., “How Nanorobots Can Avoid Phagocytosis by White Cells – Part I,” Foresight Update No. 45, 30 June 2001, pp. 10-12. See at: http://www.imm.org/Reports/Rep027.php.

3. H. Bos, W. de Souza, “Phagocytosis of yeast: a method for concurrent quantification of binding and internalization using differential interference contrast microscopy,” J. Immunol. Methods 238(21 April 2000):29-43.

4. L.A. Allen, A. Aderem, “Molecular definition of distinct cytoskeletal structures involved in complement- and Fc receptor-mediated phagocytosis in macrophages,” J. Exp. Med. 184(1 August 1996):627-637.

5. D. Cox et al., “A requirement for phosphatidylinositol 3-kinase in pseudopod extension,” J. Biol. Chem. 274(15 January 1999):1240-1247.

6. S. Greenberg, “Modular components of phagocytosis,” J. Leukoc. Biol. 66(November 1999):712-717.

7. P. Massol et al., “Fc receptor-mediated phagocytosis requires CDC42 and Rac1,” EMBO J. 17(2 November 1998):6219-6229.

8. S.J. Suchard et al., “Mitogen-activated protein kinase activation during IgG-dependent phagocytosis in human neutrophils: inhibition by ceramide,” J. Immunol. 158(15 May 1997):4961-4967.

9. E.S. Gold et al., “Amphiphysin IIm, a novel amphiphysin II isoform, is required for macrophage phagocytosis,” Immunity 12(March 2000):285-292.

10. A. Odegaard, J. Lamvik, “The effect of phenylbutazone and chloramphenicol on phagocytosis of radiolabelled Candida albicans by human monocytes cultured in vitro,” Acta Pathol. Microbiol. Scand. C 84(February 1976):37-44.

11. Kenneth Todar, “Evasion of Host Phagocytic Defenses,” University of Wisconsin-Madison, see at: http://www.bact.wisc.edu/microtextbook/disease/evadephago.html.

12. C.G. Gemmell, “Changes in expression of bacterial surface antigens induced by antibiotics and their influence on host defenses,” Pathol. Biol. (Paris) 35(December 1987):1377-1381.

13. Lynn E. Hancock, Michael S. Gilmore, “Pathogenicity of Enterococci,” in Vincent Fischetti et al., eds., Gram-Positive Pathogens, ASM Press, Washington, DC, 2000. See at: http://www.enterococcus.ouhsc.edu/lynn_revirew.asp.

14. T. Hishikawa et al., “Calcium transients during Fc receptor-mediated and nonspecific phagocytosis by murine peritoneal macrophages,” J. Cell Biol. 15(October 1991):59-66.

15. I. Ofek et al., “Nonopsonic phagocytosis of microorganisms,” Annu. Rev. Microbiol. 49(1995):239-276.

16. H.S. Kruth et al., “Characterization of patocytosis: endocytosis into macrophage surface-connected compartments,” Eur. J. Cell Biol. 78(February 1999):91-99.

17. V.S. Goldmacher, “Macrophages. Inhibition of endocytosis by anchorage to substrate,” Exp. Cell Res. 154(October 1984):632-635.

18. E.S. Gold et al., “Dynamin 2 is required for phagocytosis in macrophages,” J. Exp. Med. 190(20 December 1999):1849-1856.

19. M.A. McNiven et al., “Regulated interactions between dynamin and the actin-binding protein cortactin modulate cell shape,” J. Cell Biol. 151(2 October 2000):187-198.

20. J.R. Henley, H. Cao, M.A. McNiven, “Participation of dynamin in the biogenesis of cytoplasmic vesicles,” FASEB J. 13(December 1999):S243-S247.

21. W. Yang, R.A. Cerione, “Endocytosis: Is dynamin a blue collar or white collar worker?” Curr. Biol. 9(15 July 1999):R511-R514.

22. M.H. Stowell et al., “Nucleotide-dependent conformational changes in dynamin: evidence for a mechanochemical molecular spring,” Nat. Cell Biol. 1(May 1999):27-32; J.E. Hinshaw, “Dynamin and its role in membrane fission,” Annu. Rev. Cell Dev. Biol. 16(2000):483-519.

23. M.A. McNiven et al., “The dynamin family of mechanoenzymes: pinching in new places,” Trends Biochem. Sci. 25(March 2000):115-120.

24. J.R. Henley et al., “Dynamin-mediated internalization of caveolae,” J. Cell Biol. 141(6 April 1998):85-99.

25. J.P. Liu et al., “Calcium binds dynamin I and inhibits its GTPase activity,” J. Neurochem. 66(May 1996):2074-2081.

26. M.A. Cousin, P.J. Robinson, “Ca(2+) influx inhibits dynamin and arrests synaptic vesicle endocytosis at the active zone,” J. Neurosci. 20(1 February 2000):949-957.

27. J.A. Swanson et al., “A contractile activity that closes phagosomes in macrophages,” J. Cell Sci. 112(February 1999):307-316.

IMM would appreciate learning your thoughts on the above article.

IMM Report Number 29: Nanomedicine

In conjunction with Foresight Update 47

Volumetric Cellular Intrusiveness of Medical Nanorobots

By Robert A. Freitas Jr.
Research Scientist, Zyvex Corp.

Robert A. Freitas  Jr.
Robert A. Freitas Jr.

Medical nanorobots on cytotherapeutic missions will often need to enter the living cell to perform repairs. Such missions may require the participation of many cooperating nanorobots, or perhaps just a few but relatively large nanorobots, per cell. And so the question logically arises: How many nanorobots can safely be crammed into a single living cell? There are at least two issues here. First, how much new foreign material can be added to a cell? Second, how much of a cell’s existing volume can be replaced with foreign material with no change in total cell volume? Since we can’t yet do direct experiments with medical nanorobots and living cells, no precise answer is possible. But we can estimate the maximum volume of foreign material that the intracellular compartment might safely accommodate by examining analogous instances of cellular intrusion.

We can start by considering cell membrane elasticity. How much can the cellular membrane stretch before it breaks? The introduction of foreign material into a cell may cause intracellular volume to expand. Assuming a spherical cell shape, the change in cell volume Δ Vcell from the original cell volume Vcell is related to the change in plasma membrane area Δ Acell of an unstretched membrane of area Acell by the relations Δ Vcell /Vcell ~ ((1 + Δ Acell/Acell)3/2 – 1) and Δ Acell/Acell = Tmemb / Kmemb, where Tmemb is the isotropic tension due to membrane expansion and the area compressibility modulus Kmemb = 0.378 N/m for erythrocyte plasma membrane at 310 K and Kmemb = 0.636 N/m for leukocyte plasma membrane ([1], Section 9.4.3.2.1). Taking a conservative lysis limit of Tmemb ~ 4 x 10-3 N/m for erythrocytes, then Δ Vcell /Vcell ~ 1.6% for red cells and ~0.9% for white cells. That’s not much stretch.

However, erythrocytes are not spheres but biconcave disks with a mean volume of 94 micron3 in isotonic solution (300 mosmol). Red cells absorb water in hypotonic solution, becoming spherical at 131 mosmol with a volume of 164 micron3, demonstrating a capacity for volumetric expansion of 74% without losing membrane integrity. Other cells may permit even more expansion. For example, taking Tmemb = 1.7 N/m and Kmemb = 1.3 N/m for TB/C3 hybridoma cells and Tmemb = 1.8 N/m and Kmemb = 1.2 N/m for NS1 myeloma cells [2], then Δ Vcell /Vcell ~ 250% for hybridomas and ~300% for myelomas. These estimates are crude at best because the lipid population of the plasma membrane is constantly changing and may enlarge or contract over time.

For more than four decades, microbiologists have routinely extracted from or inserted an entire nucleus into a cell using micropipettes without compromising cell viability. Such nuclear transplantation represents a volumetric change of Δ Vcell /Vcell ~ 3-4% for the typical 20-micron human tissue cell ([1], Table 8.17) but in the case of a human leukocyte would represent a volumetric change of Δ Vcell /Vcell ~ 18% for an eosinophil, 22% for a neutrophil, 26% for a monocyte, or 51% for a lymphocyte. Decades of laboratory practice have confirmed that at least ~10-10 ml/cell or ~100 micron3/cell of foreign material (representing perhaps 1-3% of cell volume) can be safely injected into a somatic cell without any significant effect on cell viability [3]. Finally, we know that neutrophils increase volume by ~15% when stimulated in suspension, but rabbit neutrophils that migrate into the abdominal wall (cell size ~150 micron3) are +50% larger than those in the abdominal wall vasculature (~100 micron3) and human neutrophils induced by FMLP to migrate into collagen gels (~290 micron3) are 42% larger than those that did not migrate (~204 micron3) [4].

Another classic measure of tolerable volumetric intrusiveness in the context of medical nanorobots [5] is the amount of lipofuscin that can accumulate inside cells without ill effect. Lipofuscin consists of insoluble age-pigment lysosomal granules that collect in many of our cells, the accumulation starting as early in life as 11 years of age and rising with age, activity level and caloric intake, and varying with cell type. Clumps of these yellow-brown granules — typically 1-3 microns in diameter — may occupy up to 10% of the volume of heart muscle cells [6], and from 20% of brainstem neuron volume at age 20 to as much as 50% of cell volume by age 90 [7]. Lipofuscin concentrations as high as 75% have been reported in Purkinje neurons of rats subjected to protein malnutrition [8]. Elevated concentrations in heart cells appear not to increase the risk of heart attack and brain cell lipofuscin is not associated with any mental or motor abnormalities or other detrimental cellular function, although hereditary ceroid lipofuscinosis can lead to premature death. The fact that lipofuscin is an indigestible lipid peroxidation product that cannot be excreted but whose presence is usually not injurious to the cell argues strongly that cells can tolerate major volumetric replacements of protoplasm with artificial foreign bodies such as medical nanorobots while continuing to function normally. Other inert intracellular pigments are known along with a number of pathological intracellular storage diseases including Gaucher’s, Niemann-Pick, and Tay-Sachs. Noninert amyloid deposits average ~12% of pancreatic islet cell volume in patients with maturity onset diabetes [9].

Various particulate substances including microspheres and crystals have been introduced intracellularly to observe the effects on the cell. In one study [10], up to 500 polystyrene 0.26-micron beads were injected into a tissue cell and this 4.6 micron3 load did not affect the cell’s ability to transport the particles around inside as if they were tiny organelles or vesicles. A few micron3/cell of engineered nanoparticles are tolerated by living cells when employed as intracellular fluorescent reporters [11]. Cholesterol crystals have been induced to grow inside living J774 mouse peritoneal macrophages, reaching a concentration of ~120 mg cholesterol/mg protein or ~2.4% intracellular crystals by volume [12] without lethality, though excessive intracellular crystallization (e.g., of drug molecules) can lead to problems such as acute renal failure and intracellular crystals have been found inside chondrocytes in certain crystal deposition diseases. A useful and simple experiment that could be done today would be to microinject various cell types with progressively larger loads of chemically inert diamond microparticles, noting the effect (if any) on cell motility, behavior, and metabolic function.

Interestingly, Pseudomonas stutzeri AG259, a species of bacterium isolated from silver mines, protects itself from the usual bactericidal effect of silver ions by sequestering triangular and hexagonal insoluble nanocrystals of Ag0 and Ag2S (believed to be acanthite, a stable crystalline form of silver sulfide) intracellularly in vacuole-like granules in the periplasmic space [13]. In one photomicrograph, several crystals ranging from 90-200 nm in diameter are visible inside a living bacterial cell ~800 nm in diameter, suggesting a total inert particulate ~13% volumetric intrusiveness.

We can obtain yet another perspective on cellular intrusiveness by considering the phagocytes — specialized cells optimized for ingestion of foreign particles [14]. Latex or polystyrene beads are among the most popular particles for phagocyte ingestion burden experiments. Guinea pig neutrophils can ingest up to 3.8% of cell volume in 3-micron polystyrene beads, but only 3.0% of cell volume of 0.3 micron beads. Peritoneal phagocytes from striped bass each ingested an average of four 3-micron latex beads during a 30-minute incubation time [15], giving a phagocytic capacity of ~64 micron3/phagocyte or ~4% of cell volume. Rabbit alveolar macrophages cultured in suspensions or on monolayers of latex particles internalized a maximum of 45 1-micron particles (45 micron3/cell or ~3% of cell volume) and 10 2-micron particles (~80 micron3/cell or ~5% of cell volume) at saturation [16]. Another study of rat alveolar macrophages confirmed particle burdens exceeding 15 2-micron microspheres (~63 micron3 or ~4% of cell volume) [17]. Murine bone-marrow macrophages that are only 13.8 microns in diameter can ingest IgG-opsonized beads up to 20 microns in diameter [18], representing an amazing ~200% of cell volume. Of course, phagocytes that eat too many latex microspheres develop impaired mobility, and some particles are highly toxic to phagocytes — just 0.05 µg of silica per 106 macrophages [19], or 0.002% of cell volume assuming 1166 micron3 per rat alveolar macrophage, is cytotoxic.

What about inorganic particles? Rat alveolar macrophages ingested at least ~1 micron3/cell of iron oxide particles (~0.1% of cell volume) without ill effect in one experiment [20], but another experiment [21] found up to 72 spherical 2.6-micron iron oxide particles (~663 micron3) had been nonfatally ingested by human alveolar macrophages each of mean volume 4990 micron3, a cell burden of ~13% foreign particles by volume. Murine macrophages suffer only ~10% mortality from ingesting up to 2500 alumina ceramic (sapphire) 0.6-micron particles, or ~10% of cell volume, although mortality rises to ~30% from ingesting a similar volume concentration of 2-micron particles [22]. Micrographs of live mouse peritoneal macrophages [23] and human monocytes [24] that have been induced to ingest diamond dust particles up to 5 microns in diameter appear to have internalized particles amounting to 10-20% of their cell volume. A particle burden “overload criterion” (i.e., producing macrophage immobilization) of ~600 micron3 per rat alveolar macrophage (a ~50% cellular volumetric burden for 1166 micron3 cells) has been proposed by Oberdorster et al. [25].

Living cells are often seen swimming around inside larger living cells. Are there any obvious volumetric limits? Individual ~200 micron3 lymphocytes have been observed circulating for hours inside larger living cells (~3-5% volume fraction) with no evident ill effect, a phenomenon called emperipolesis ([1], Section 8.5.3.12). While neutrophils and macrophages are both found in mammalian lungs and neither cell phagocytoses the other in significant quantities, alveolar macrophages containing neutrophils have been observed. Neutrophils that have undergone apoptosis are taken up by macrophages, with mean uptake of 3 neutrophils per macrophage [26]. Taking nonmigratory human neutrophils as 204 micron3 and human alveolar macrophages as 4990 micron3, the uptake represents ~12% of macrophage cell volume.

Cells may also harbor smaller pathogens which are usually volumetrically harmless to the host. Perhaps the best-known example is the case of the bacteriophage T4. A single Escherichia coli bacterium injected with a single T4 phage virion at 37oC in rich media lyses after 25-30 minutes, releasing 100-200 phage particles that have replicated themselves inside [27]. Taking E. coli volume as 0.6 micron3 ([1], Section 10.4.2.5) and phage T4 volume as ~200,000 nm3, then the bacteriophage particle load on E. coli at lysis is 3-7% of bacterial cell volume. In human cells, the tuberculosis bacterium enters the alveolar macrophage, which transports the intruder into the blood, the lymphatic system, and elsewhere. Each ~1 micron3 bacillus that hitches a ride in this manner represents a volumetric intrusion of 0.02% of macrophage volume. Other intracellular microorganisms such as Listeria (~0.25 micron3) and Shigella (~2 micron3), once free in the cytoplasm, are propelled “harmlessly” through the cytosol via continuous cytoskeleton-linked actin polymerization ([1], Section 9.4.6). Macrophages infected with Listeria have been observed with ~2% of their volume co-opted by the microbes (~100 organisms) [28]. While some motile intracellular parasites such as Tyzzer may cause disarrangement and depopulation of host cell organelles by the movement of their peritrichous flagella, other motile intracellular parasites such as the spotted fever-group rickettsiae [29] spread rapidly from cell to cell by actin-based movement but do not cause lysis of the host cell, and typhus-group rickettsiae [29] multiply in host cells to great numbers without profound damage (until cell lysis finally occurs) — providing a more positive intrusiveness benchmark for future medical nanorobots.

Copyright 2001 Robert A. Freitas Jr. All Rights Reserved

References

1. Robert A. Freitas Jr., Nanomedicine, Volume I: Basic Capabilities, Landes Bioscience, Georgetown, TX, 1999; see at: http://www.nanomedicine.com.

2. Z. Zhang, M. Al-Rubeai, C.R. Thomas, “Estimation of disruption of animal cells by turbulent capillary flow,” Biotechnology and Bioengineering 42(1993):987-993.

3. Julio E. Celis, “Microinjection of somatic cells with micropipettes: comparison with other transfer techniques,” Biochem. J. 223(1984):281-291.

4. G.S. Worthen, P.M. Henson, S. Rosengren, G.P. Downey, D.M. Hyde, “Neutrophils increase volume during migration in vivo and in vitro,” Am. J. Respir. Cell Mol. Biol. 10(January 1994):1-7.

5. K. Eric Drexler, Engines of Creation: The Coming Era of Nanotechnology, Anchor Press/Doubleday, New York, 1986.

6. Bernard L. Strehler, Donald D. Mark, Albert S. MilΔ Van, Malcolm V. Gee, “Rate and magnitude of age pigment accumulation in the human myocardium,” Journal of Gerontology 14(1959):430-439.

7. Christopher West, “A quantitative study of lipofuscin accumulation with age in normals and individuals with Down’s syndrome, phenylketonuria, progeria and transneuronal atrophy,” J. Comp. Neurol. 186(1 July 1979):109-116.

8. T.J. James, S.P. Sharma, “Regional and lobular variation in neuronal lipofuscinosis in rat cerebellum: influence of age and protein malnourishment,” Gerontology 41(1995):213-228 (Suppl 2).

9. P. Westermark, E. Wilander, “The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus,” Diabetologia 15(November 1978):417-421.

10. M.C. Beckerle, “Microinjected fluorescent polystyrene beads exhibit saltatory motion in tissue culture cells,” J. Cell Biol. 98(June 1984):2126-2132.

11. J. Lu, Z. Rosenzweig, “Nanoscale fluorescent sensors for intracellular analysis,” Fresenius J. Anal. Chem. 366(March-April 2000):569-575.

12. G. Kellner-Weibel, P.G. Yancey, W.G. Jerome, T. Walser, R.P. Mason, M.C. Phillips, G.H. Rothblat, “Crystallization of free cholesterol in model macrophage foam cells,” Arterioscler. Thromb. Vasc. Biol. 19(August 1999):1891-1898; see at: http://atvb.ahajournals.org/cgi/content/full/19/8/1891.

13. Tanja Klaus, Ralph Joerger, Eva Olsson, and Claes-Göran Granqvist, “Silver-based crystalline nanoparticles, microbially fabricated,” Proc. Natl. Acad. Sci. (USA) 96(23 November 1999):13611-13614; 96(7 December 1999):14183-14185 (comment).

14. Robert A. Freitas Jr., “How Nanorobots Can Avoid Phagocytosis by White Cells – Part I,” Foresight Update No. 45, 30 June 2001, pp. 10-12; http://www.imm.org/Reports/Rep027.php; and “Part II,” Foresight Update No. 46, 30 September 2001, pp. 18-20; http://www.imm.org/Reports/Rep028.php.

15. R.E. Polonio, R.E. Wolke, S.A. MacLean, J.F. Sperry, “An in vitro assay to measure phagocytosis in striped bass hybrids,” Fish Shellfish Immunol. 10(July 2000):405-418.

16. Y. Kubota, S. Takahashi, O. Matsuoka, “Dependence on particle size in the phagocytosis of latex particles by rabbit alveolar macrophages cultured in vitro,” J. Toxicol. Sci. 8(August 983):189-195

17. B.E. Lehnert, Y.E. Valdez, G.L. Tietjen, “Alveolar macrophage-particle relationships during lung clearance,” Am. J. Respir. Cell Mol. Biol. 1(August 1989):145-154.

18. G.J. Cannon, J.A. Swanson, “The macrophage capacity for phagocytosis,” J. Cell Sci. 101(April 1992):907-913.

19. E.D. Bateman, R.J. Emerson, P.J. Cole, “A study of macrophage-mediated initiation of fibrosis by asbestos and silica using a diffusion chamber technique,” Br. J. Exp. Pathol. 63(August 1982):414-425.

20. B.E. Lehnert, P.E. Morrow, “Association of 59iron oxide with alveolar macrophages during alveolar clearance,” Exp. Lung Res. 9(1985):1-16.

21. John C. Lay, William D. Bennett, Chong S. Kim, Robert B. Devlin, Philip A. Bromberg, “Retention and intracellular distribution of instilled iron oxide particles in human alveolar macrophages,” Am. J. Respir. Cell Mol. Biol. 18(May 1998):687-695.

22. Isabelle Catelas, Alain Petit, Richard Marchand, David J. Zukor, L’Hocine Yahia, Olga L. Huk, “Cytotoxicity and macrophage cytokine release induced by ceramic and polyethylene particles in vitro,” J. Bone Joint Surg. Br. 81(May 1999):516-521.

23. A.C. Allison, J.S. Harington, M. Birbeck, “An examination of the cytotoxic effects of silica on macrophages,” J. Exp. Med. 124(1966):141-154.

24. L. Nordsletten, A.K. Hogasen, Y.T. Konttinen, S. Santavirta, P. Aspenberg, A.O. Aasen, “Human monocytes stimulation by particles of hydroxyapatite, silicon carbide and diamond: in vitro studies of new prosthesis coatings,” Biomaterials 17(August 1996):1521-1527.

25. G. Oberdorster, J. Ferin, P.E. Morrow, ‘Volumetric loading of alveolar macrophages (AM): a possible basis for diminished AM-mediated particle clearance,” Exp. Lung Res. 18(January-March 1992):87-104.

26. L.C. Meagher, J.S. Savill, A. Baker, R.W. Fuller, C. Haslett, “Phagocytosis of apoptotic neutrophils does not induce macrophage release of thromoboxane B2,” J. Leukoc. Biol. 52(September 1992):269-273.

27. A.D. Doerman, “Lysis and lysis inhibition with Escherichia coli bacteriophage,” J. Bacteriol. 55(1948):257-275.

28. Amy L. Decatur, Daniel A. Portnoy, “A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity,” Science 290(3 November 2000):992-995.

29. T. Hackstadt, “The biology of rickettsiae,” Infect. Agents Dis. 5(June 1996):127-143.

IMM would appreciate learning your thoughts on the above article.

Primary Sidebar

Support IMM

 

Custom Google Search

Google Custom Search

Related Sites

  • Foresight Institute
  • Eric Drexler
  • Ralph Merkle
  • Robert Freitas
  • Zettl Research Group
  • Schafmeister Group

Footer